PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Rimiducid

Drugs in development · updated 30 October 2026

Rimiducid: clinical trials and development status

Other names and codes: AP1903, AP 1903 reagent

NLM verified identityNot approved in the USNo EMA authorisation

As of 30 October 2026 Rimiducid is in 17 active clinical trials (recruiting or ongoing, phases I–III) for 40 diseases. The most advanced phase is II.

17Active trials
IIMost advanced phase
40Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Rimiducid and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov. Showing 30 of 40 diseases.

DiseaseMost advanced phaseActive trialsReference trial
Myelodysplastic SyndromesI–II5NCT01744223
LeukemiaI–II4NCT03301168
LymphomaI–II4NCT01744223
Precursor lymphoblastic lymphoma/leukemiaI–II4NCT01744223
Acute myeloid leukemiaI–II3NCT01744223
Hematologic neoplasmI–II3NCT03301168
Non-Hodgkin lymphomaI–II2NCT03301168
Stomach neoplasmI–II2NCT07509008
Aplastic anemiaI–II1NCT03301168
CytopeniaI–II1NCT03301168
Graft-versus-host diseaseI–II1NCT01744223
Hodgkin lymphomaII1NCT07164469
MetastasisI–II1NCT07509008
OsteopetrosisI–II1NCT03301168
Primary immunodeficiency diseaseI–II1NCT03301168
ThymomaI–II1NCT07598955
Thymus epithelial tumorI–II1NCT07598955
Breast neoplasmI3NCT07553390
Colorectal neoplasmI2NCT06358430
Cytokine release syndromeI2NCT03696784
Immune System DiseasesI2NCT03696784
Immunoproliferative disorderI2NCT03696784
Multiple myelomaI2NCT04960579
Residual neoplasmI2NCT06358430
B-cell lymphomaI1NCT03696784
Diffuse large B-cell lymphomaI1NCT06014762
Epstein–Barr virus infectionI1NCT01494103
Head and neck squamous cell carcinomaI1NCT05239143
Hemophagocytic lymphohistiocytosisI1NCT01494103
Leukemia, Myelogenous, Chronic, BCR-ABL PositiveI1NCT01494103

Everything on Rimiducid

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch